Rebecca V Levy1, Kimberly J Reidy2, Thu H Le3, Victor David4, Cheryl Winkler4, Yunwen Xu5, Bradley Warady6, Susan Furth7, Frederick Kaskel2, Michal L Melamed8. 1. Department of Medicine, Division of Nephrology, School of Medicine and Dentistry, University of Rochester, Rochester, New York. Electronic address: rebecca_levy@urmc.rochester.edu. 2. Department of Pediatrics, Division of Pediatric Nephrology, Montefiore Medical Center, Bronx, New York. 3. Department of Medicine, Division of Nephrology, School of Medicine and Dentistry, University of Rochester, Rochester, New York. 4. Basic Science Laboratory, Center for Cancer Research, Frederick National Laboratory, Frederick, Maryland. 5. Department of Epidemiology, School of Public Health, Johns Hopkins University, Baltimore, Maryland. 6. Department of Pediatrics, Division of Pediatric Nephrology, Children's Mercy, Kansas City, Missouri. 7. Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 8. Department of Medicine, Division of Nephrology, Albert Einstein College of Medicine, Bronx, New York.
Abstract
RATIONALE & OBJECTIVE: Loss of function of the product of the GSTM1 gene has been implicated in rapid progression of adult chronic kidney disease (CKD). Its role in pediatric CKD has not been previously described. STUDY DESIGN: Secondary analysis of a prospective observational cohort examining the association between deletions in GSTM1 and progression of CKD. SETTING & PARTICIPANTS: We used data and samples from the prospective Chronic Kidney Disease in Children (CKiD) cohort aged 1-16 years at enrollment with CKD. EXPOSURE: We defined the exposure as fewer than 2 GSTM1 alleles on real-time polymerase chain reaction amplification. OUTCOME: The primary outcome was a composite of 50% decrease in estimated glomerular filtration rate (eGFR) or start of kidney replacement therapy. Secondary outcomes included remission of proteinuria in children with glomerular disease and cardiovascular complications. ANALYTICAL APPROACH: The primary analysis was by Cox proportional hazards model. Analysis was adjusted for age, sex, race, ethnicity, body mass index category, diagnosis category, and eGFR. RESULTS: The analysis included 674 children. Their mean age at most recent visit was 11.9 years; 61% were male, and 20% were Black. There were 241 occurrences of the primary outcome at the time of analysis. After adjustment for baseline characteristics, the risk of progression of CKD for exposed children was 1.94 (95% CI, 1.27-2.97). The effect size was similar with either 1 or 2 deletions (autosomal dominant inheritance). The relationships between number of functional GSTM1 alleles and prespecified secondary outcomes were not statistically significant after adjustment. LIMITATIONS: Missing data, especially for secondary outcomes, and relatively small sample size compared to genetic studies in adults. CONCLUSIONS: GSTM1 deletion is associated with more rapid progression of pediatric CKD after adjustment in this large prospective cohort. No statistically significant associations were seen with secondary outcomes. If replicated, these findings may inform development of interventions for CKD in children.
RATIONALE & OBJECTIVE: Loss of function of the product of the GSTM1 gene has been implicated in rapid progression of adult chronic kidney disease (CKD). Its role in pediatric CKD has not been previously described. STUDY DESIGN: Secondary analysis of a prospective observational cohort examining the association between deletions in GSTM1 and progression of CKD. SETTING & PARTICIPANTS: We used data and samples from the prospective Chronic Kidney Disease in Children (CKiD) cohort aged 1-16 years at enrollment with CKD. EXPOSURE: We defined the exposure as fewer than 2 GSTM1 alleles on real-time polymerase chain reaction amplification. OUTCOME: The primary outcome was a composite of 50% decrease in estimated glomerular filtration rate (eGFR) or start of kidney replacement therapy. Secondary outcomes included remission of proteinuria in children with glomerular disease and cardiovascular complications. ANALYTICAL APPROACH: The primary analysis was by Cox proportional hazards model. Analysis was adjusted for age, sex, race, ethnicity, body mass index category, diagnosis category, and eGFR. RESULTS: The analysis included 674 children. Their mean age at most recent visit was 11.9 years; 61% were male, and 20% were Black. There were 241 occurrences of the primary outcome at the time of analysis. After adjustment for baseline characteristics, the risk of progression of CKD for exposed children was 1.94 (95% CI, 1.27-2.97). The effect size was similar with either 1 or 2 deletions (autosomal dominant inheritance). The relationships between number of functional GSTM1 alleles and prespecified secondary outcomes were not statistically significant after adjustment. LIMITATIONS: Missing data, especially for secondary outcomes, and relatively small sample size compared to genetic studies in adults. CONCLUSIONS: GSTM1 deletion is associated with more rapid progression of pediatric CKD after adjustment in this large prospective cohort. No statistically significant associations were seen with secondary outcomes. If replicated, these findings may inform development of interventions for CKD in children.
Authors: S Garte; L Gaspari; A K Alexandrie; C Ambrosone; H Autrup; J L Autrup; H Baranova; L Bathum; S Benhamou; P Boffetta; C Bouchardy; K Breskvar; J Brockmoller; I Cascorbi; M L Clapper; C Coutelle; A Daly; M Dell'Omo; V Dolzan; C M Dresler; A Fryer; A Haugen; D W Hein; A Hildesheim; A Hirvonen; L L Hsieh; M Ingelman-Sundberg; I Kalina; D Kang; M Kihara; C Kiyohara; P Kremers; P Lazarus; L Le Marchand; M C Lechner; E M van Lieshout; S London; J J Manni; C M Maugard; S Morita; V Nazar-Stewart; K Noda; Y Oda; F F Parl; R Pastorelli; I Persson; W H Peters; A Rannug; T Rebbeck; A Risch; L Roelandt; M Romkes; D Ryberg; J Salagovic; B Schoket; J Seidegard; P G Shields; E Sim; D Sinnet; R C Strange; I Stücker; H Sugimura; J To-Figueras; P Vineis; M C Yu; E Taioli Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-12 Impact factor: 4.254
Authors: Joseph T Flynn; David C Kaelber; Carissa M Baker-Smith; Douglas Blowey; Aaron E Carroll; Stephen R Daniels; Sarah D de Ferranti; Janis M Dionne; Bonita Falkner; Susan K Flinn; Samuel S Gidding; Celeste Goodwin; Michael G Leu; Makia E Powers; Corinna Rea; Joshua Samuels; Madeline Simasek; Vidhu V Thaker; Elaine M Urbina Journal: Pediatrics Date: 2017-08-21 Impact factor: 7.124
Authors: Bradley A Warady; Alison G Abraham; George J Schwartz; Craig S Wong; Alvaro Muñoz; Aisha Betoko; Mark Mitsnefes; Frederick Kaskel; Larry A Greenbaum; Robert H Mak; Joseph Flynn; Marva M Moxey-Mims; Susan Furth Journal: Am J Kidney Dis Date: 2015-03-19 Impact factor: 8.860
Authors: Jamison Chang; Jennie Z Ma; Qing Zeng; Sylvia Cechova; Adam Gantz; Caroline Nievergelt; Daniel O'Connor; Michael Lipkowitz; Thu H Le Journal: Am J Physiol Renal Physiol Date: 2012-12-05
Authors: Janis M Dionne; Shuai Jiang; Derek K Ng; Joseph T Flynn; Mark M Mitsnefes; Susan L Furth; Bradley A Warady; Joshua A Samuels Journal: Hypertension Date: 2021-06-01 Impact factor: 9.897
Authors: B E Gutiérrez-Amavizca; R Orozco-Castellanos; R Ortíz-Orozco; J Padilla-Gutiérrez; Y Valle; N Gutiérrez-Gutiérrez; G García-García; M Gallegos-Arreola; L E Figuera Journal: Indian J Nephrol Date: 2013-11
Authors: Julian Little; Julian P T Higgins; John P A Ioannidis; David Moher; France Gagnon; Erik von Elm; Muin J Khoury; Barbara Cohen; George Davey-Smith; Jeremy Grimshaw; Paul Scheet; Marta Gwinn; Robin E Williamson; Guang Yong Zou; Kim Hutchings; Candice Y Johnson; Valerie Tait; Miriam Wiens; Jean Golding; Cornelia van Duijn; John McLaughlin; Andrew Paterson; George Wells; Isabel Fortier; Matthew Freedman; Maja Zecevic; Richard King; Claire Infante-Rivard; Alex Stewart; Nick Birkett Journal: PLoS Med Date: 2009-02-03 Impact factor: 11.069